Prana Biotechnology Limited (ADR) (PRAN) Reaches $2.25 After 5.00% Up Move; 4 Analysts Bullish KemPharm (KMPH)

June 20, 2017 - By marketbeat

Among 4 analysts covering KemPharm (NASDAQ:KMPH), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. KemPharm had 7 analyst reports since August 14, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Outperform” rating and $22 target in Friday, August 14 report. The rating was reinitiated by Canaccord Genuity with “Buy” on Tuesday, December 20. Oppenheimer maintained KemPharm Inc (NASDAQ:KMPH) on Friday, September 18 with “Outperform” rating. The company was maintained on Friday, May 6 by RBC Capital Markets. Canaccord Genuity maintained it with “Buy” rating and $34 target in Thursday, September 17 report. See KemPharm Inc (NASDAQ:KMPH) latest ratings:

The stock of Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) is a huge mover today! About 68,086 shares traded or 177.49% up from the average. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has declined 38.63% since June 20, 2016 and is downtrending. It has underperformed by 55.33% the S&P500.The move comes after 9 months positive chart setup for the $19.90 million company. It was reported on Jun, 20 by Barchart.com. We have $2.36 PT which if reached, will make NASDAQ:PRAN worth $995,000 more.

About 36,579 shares traded or 63.71% up from the average. KemPharm Inc (NASDAQ:KMPH) has declined 32.16% since June 20, 2016 and is downtrending. It has underperformed by 48.86% the S&P500.

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The company has market cap of $57.25 million. The Firm is engaged in the discovery and development of prodrugs. It currently has negative earnings. The Firm uses its Ligand Activated Therapy platform technology to create prodrugs.

Prana Biotechnology Limited is a development-stage medical biotechnology company. The company has market cap of $19.90 million. The Firm is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders. It currently has negative earnings. The Company’s lead product candidates are PBT2 and PBT434.